Literature DB >> 33946446

Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy.

Dean F Loporchio1, Emily K Tam1, Jane Cho1, Jaeyoon Chung2, Gyungah R Jun2, Weiming Xia3,4, Marissa G Fiorello1, Nicole H Siegel1, Steven Ness1, Thor D Stein5,6,7, Manju L Subramanian1.   

Abstract

In this study, we compare the vitreous cytokine profile in patients with proliferative diabetic retinopathy (PDR) to that of patients without PDR. The identification of novel cytokines involved in the pathogenesis of PDR provides candidate therapeutic targets that may stand alone or work synergistically with current therapies in the management of diabetic retinopathy. Undiluted vitreous humor specimens were collected from 74 patients undergoing vitrectomy for various vitreoretinal disorders. Quantitative immunoassay was performed for a panel of 36 neuroinflammatory cytokines in each specimen and assessed to identify differences between PDR (n = 35) and non-PDR (n = 39) patients. Levels of interleukin-8 (IL-8), IL-15, IL-16, vascular endothelial growth factor (VEGF), VEGF-D, c-reactive protein (CRP), serum amyloid-A (SAA), and intracellular adhesion molecule-1 (ICAM1) were significantly increased in the vitreous of PDR patients compared to non-PDR patients (p < 0.05). We report novel increases in IL-15 and IL-16, in addition to the expected VEGF, in the human vitreous humor of patients with PDR. Additionally, we confirm the elevation of ICAM-1, VCAM-1, SAA, IL-8 and CRP in the vitreous of patients with PDR, which has previously been described.

Entities:  

Keywords:  basic fibroblast growth factor; diabetic retinopathy; interleukin-15; interleukin-16; interleukin-8; neuroinflammatory markers; quantitative immunoassay; vascular endothelial growth factor; vitreous cytokines

Year:  2021        PMID: 33946446     DOI: 10.3390/cells10051069

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  35 in total

Review 1.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

Authors:  M J Cross; L Claesson-Welsh
Journal:  Trends Pharmacol Sci       Date:  2001-04       Impact factor: 14.819

2.  Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease.

Authors:  Ponnalagu Murugeswari; Dhananjay Shukla; Anand Rajendran; Ramasamy Kim; Perumalsamy Namperumalsamy; Veerappan Muthukkaruppan
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

3.  Development of proliferative diabetic retinopathy in African-Americans and whites with type 1 diabetes.

Authors:  C L Arfken; P L Reno; J V Santiago; R Klein
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

4.  Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion.

Authors:  Yukihiko Suzuki; Mitsuru Nakazawa; Kaori Suzuki; Hitoshi Yamazaki; Yasuhiro Miyagawa
Journal:  Jpn J Ophthalmol       Date:  2011-05-03       Impact factor: 2.447

5.  Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study.

Authors:  C Hernández; R Burgos; A Cantón; J García-Arumí; R M Segura; R Simó
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

6.  Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription.

Authors:  David M Center; William W Cruikshank; Yujun Zhang
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

7.  Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.

Authors:  B Kenarova; L Voinov; C Apostolov; R Vladimirova; A Misheva
Journal:  Eur J Ophthalmol       Date:  1997 Jan-Mar       Impact factor: 1.922

8.  The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology.

Authors:  Stepan Rusnak; Jindra Vrzalova; Marketa Sobotova; Lenka Hecova; Renata Ricarova; Ondrej Topolcan
Journal:  J Ophthalmol       Date:  2015-09-27       Impact factor: 1.909

9.  Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Ghulam Mohammad; Mohammad Mairaj Siddiquei; Kaiser Alam; Ahmed Mousa; Ghislain Opdenakker
Journal:  Lipids Health Dis       Date:  2014-12-11       Impact factor: 3.876

10.  Correlation of Aqueous, Vitreous, and Plasma Cytokine Levels in Patients With Proliferative Diabetic Retinopathy.

Authors:  Frances Wu; Audrey Phone; Ricardo Lamy; Dahui Ma; Sawarin Laotaweerungsawat; Yi Chen; Tong Zhao; Wei Ma; Fuyan Zhang; Catherine Psaras; Jay M Stewart
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

View more
  1 in total

1.  The Aflibercept-Induced MicroRNA Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients Detected by Next-Generation Sequencing.

Authors:  Ju Guo; Pengyi Zhou; Zhenhui Liu; Fangfang Dai; Meng Pan; Guangqi An; Jinfeng Han; Liping Du; Xuemin Jin
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.